Gyre Therapeutics (GYRE) Current Deferred Revenue (2010 - 2025)
Gyre Therapeutics (GYRE) posted quarterly Current Deferred Revenue of $14000.0 for Q4 2025, down 77.05% year-over-year from $61000.0 in Q4 2024, and down 75.86% quarter-over-quarter from $58000.0 in Q3 2025.
Gyre Therapeutics (GYRE) Current Deferred Revenue (2010 - 2025) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Current Deferred Revenue for 15 consecutive years, with $14000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue fell 77.05% year-over-year to $14000.0; the TTM figure through Dec 2025 stood at $14000.0 (down 77.05% YoY), while the FY2025 annual figure was $14000.0, down 77.05% from the prior year.
- Current Deferred Revenue eased to $14000.0 in Q4 2025 per GYRE's latest filing, from $58000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $2.0 million in Q2 2021 and bottomed at $14000.0 in Q4 2025.
- Historically, Current Deferred Revenue has averaged $378923.1 across 5 years, with a median of $58000.0 in 2025.
- On a YoY basis, Current Deferred Revenue climbed as much as 517.58% in 2021 and fell as far as 88.4% in 2021.
- Gyre Therapeutics' Current Deferred Revenue stood at $230000.0 in 2021, then sank by 36.96% to $145000.0 in 2022, then sank by 73.1% to $39000.0 in 2023, then surged by 56.41% to $61000.0 in 2024, then plunged by 77.05% to $14000.0 in 2025.
- Business Quant data shows GYRE's Current Deferred Revenue at $14000.0 in Q4 2025, $58000.0 in Q3 2025, and $28000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 145,000.00 |
| Dec 31, 2021 | 230,000.00 |
| Sep 30, 2021 | 853,000.00 |
| Jun 30, 2021 | 2.04 Mn |
| Mar 31, 2021 | 1.33 Mn |
| Dec 31, 2020 | 1.98 Mn |
| Sep 30, 2020 | 764,000.00 |
| Jun 30, 2020 | 330,000.00 |
| Dec 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 15,000.00 |
| Sep 30, 2018 | 13,000.00 |
| Jun 30, 2018 | 10,000.00 |